Hyposensitizing therapy with standard antigenic extracts: an important source of thimerosal sensitization

Area of Science:

• Allergy and Immunology
• Dermatology
• Ophthalmology

Background:

• Thimerosal, an ethylmercury-containing preservative, is used in various medical products.
• Understanding thimerosal sensitization is crucial for managing allergic reactions.
• Previous studies have indicated potential links between thimerosal exposure and sensitization.

Purpose of the Study:

• To determine the frequency of thimerosal sensitization across different subject groups.
• To identify potential sources of thimerosal sensitization.
• To evaluate the clinical relevance of thimerosal sensitization in various conditions.

Main Methods:

• Cross-sectional study involving five distinct groups: military recruits, healthy subjects, patients with asthma/rhinitis on immunotherapy, patients with allergic contact dermatitis, and patients with allergic contact conjunctivitis.
• Patch testing was employed to assess thimerosal sensitization.
• Clinical histories and exposure data were collected and compared across groups.

Main Results:

• Patients with allergic contact conjunctivitis and those undergoing immunotherapy showed significantly higher rates of thimerosal sensitization compared to healthy subjects.
• Patients with allergic contact dermatitis had a higher incidence of positive patch tests than healthy subjects, though the sensitization source was unclear.
• Ophthalmic solutions and thimerosal-preserved allergen extracts were identified as significant sources of sensitization.

Conclusions:

• Thimerosal sensitization is notably prevalent in patients with allergic contact conjunctivitis and those receiving immunotherapy.
• Ophthalmic preparations and allergen immunotherapy extracts represent important exposure routes for thimerosal.
• The clinical significance of thimerosal sensitization is most evident in allergic contact conjunctivitis, with local reactions also noted in immunotherapy patients.